Skip to main content

Table 1 Synergistic interaction between JAKi and gefitinib in variety of molar ratios on the viability of SKOV3 cells

From: Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer

JAKi: Gefitinib

Combination index (CI)

IC50 (μ M)

ED50

ED75

ED90

JAKi

Gefitinib

1:3

0.7

0.14

0.052

0.87

2.61

1:2

0.34

0.092

0.044

0.55

1.09

1:1

0.32

0.11

0.048

0.74

0.74

2:1

0.35

0.13

0.061

1.01

0.55

4:1

0.35

0.16

0.08

1.15

0.29

8:1

0.48

0.26

0.15

1.71

0.21

Back to article page

Molecular Cancer

ISSN: 1476-4598